ReviewPharmaceutics2022
Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Probiotics in asthma: immunoregulatory mechanisms and emerging opportunities for respiratory delivery-a narrative review.Translational pediatrics · 2026Review
- The Role of Gut Microbiota-Derived Extracellular Vesicles in Post-Anesthesia Neuroinflammation and Cognitive Impairment.Journal of Korean Neurosurgical Society · 2026Review
- Gut microbiota-derived extracellular vesicles: novel perspectives from host-microbe interactions to therapeutic applications.Journal of physiology and biochemistry · 2026Review
- Molecular mechanisms of virulence in Enterococcus faecium: integrating Esp, Acm, regulatory RNA networks in multidrug resistant nosocomial infections.Archives of microbiology · 2026Review
- Probiotic membrane vesicles: emerging tools for disease treatment.Microbiome research reports · 2025Review
- Article
- Probiotic-derived extracellular vesicles: a novel weapon against viral infections.Bioscience of microbiota, food and health · 2025Review
- Emerging role of gut microbiota extracellular vesicle in neurodegenerative disorders and insights on their therapeutic management.iMetaOmics · 2024Review
- Probiotics alleviate chronic ethanol exposure-induced anxiety-like behavior and hippocampal neuroinflammation in male mice through gut microbiota-derived extracellular vesicles.Journal of nanobiotechnology · 2024Article
- Improved Isolation Optimizes Downstream Application of Extracellular Vesicles Derived fromMicroorganisms · 2024Article
- Effect of gut microbiota-derived metabolites and extracellular vesicles on neurodegenerative disease in a gut-brain axis chip.Nano convergence · 2024Article
- The Recent Progress of the Cellulose-Based Antibacterial Hydrogel.Gels (Basel, Switzerland) · 2024Review
- Membrane Vesicles as Drug Delivery Systems: Source, Preparation, Modification, Drug Loading, In Vivo Administration and Biodistribution, and Application in Various Diseases.Pharmaceutics · 2023Article
- Lactic Acid Bacteria (LAB) and Neuroprotection, What Is New? An Up-To-Date Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Extracellular Vesicles of Probiotics: Shedding Light on the Biological Activity and Future Applications.Pharmaceutics · 2023Review
- Bio-Inspired Drug Delivery Systems: From Synthetic Polypeptide Vesicles to Outer Membrane Vesicles.Pharmaceutics · 2023Review
- Emerging therapeutic role of gut microbial extracellular vesicles in neurological disorders.Frontiers in neuroscience · 2023Review
- Gram-negative bacterial sRNAs encapsulated in OMVs: an emerging class of therapeutic targets in diseases.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multidrug-resistant (MDR) superbugs can breach the blood-brain barrier (BBB), leading to a continuous barrage of pro-inflammatory modulators and induction of severe infection-related pathologies, including meningitis and brain abscess. Both broad-spectrum or species-specific antibiotics (β-lactamase inhibitors, polymyxins, vancomycin, meropenem, plazomicin, and sarecycline) and biocompatible poly (lactic-co-glycolic acid) (PLGA) nanoparticles have been used to treat these infections. However, new therapeutic platforms with a broad impact that do not exert off-target deleterious effects are needed. Membrane vesicles or extracellular vesicles (EVs) are lipid bilayer-enclosed particles with therapeutic potential owing to their ability to circumvent BBB constraints. Bacteria-derived EVs (bEVs) from gut microbiota are efficient transporters that can penetrate the central nervous system. In fact, bEVs can be remodeled via surface modification and CRISPR/Cas editing and, thus, represent a novel platform for conferring protection against infections breaching the BBB. Here, we discuss the latest scientific research related to gut microbiota- and probiotic-derived bEVs, and their therapeutic modifications, in terms of regulating neurotransmitters and inhibiting quorum sensing, for the treatment of neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases. We also emphasize the benefits of probiotic-derived bEVs to human health and propose a novel direction for the development of innovative heterologous expression systems to combat BBB-crossing pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.